SK Biopharmaceuticals Aims to Become 'Big Biotech'

SK Biopharmaceuticals, a South Korean-based biotech, has announced its new strategy to propel the company towards becoming a global “big biotech.”

Donghoon Lee, CEO of SK Biopharmaceuticals, recently presented the vision at a press conference in Seoul, including plans to globalize and mobilize its therapeutic modalities and platforms of radiopharmaceutical therapy (RPT) and targeted protein degradation (TPD).

SK Biopharma will work with TerraPower, a US-based nuclear innovation company that SK group is one of the largest investors. It will also expand into oncology, an area with sizeable therapeutic potential, as it seeks to become a major player in the RPT arena in Asia and the US.

The recent acquisition of Proteovant Therapeutics, a US-based biotech, will help to reinforce its TPD platform. This move enabled SK Biopharma to have a global R&D center for cancer therapy and adopt TPD technology for future drug development for central nervous system (CNS) diseases.

Lee outlined how the company will venture into new cell and gene therapies with SK Inc. and SK Pharmteco, utilized shared resources in R&D, production, and distribution between the SK Group entities, forming the entire “bio value chain.”

The company also plans to launch its second commercial product via an acquisition by 2025, which fits their medium to long-term strategic goals.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.